de Herder WW. When and how to use somatostatin analogues. Endocrinol Metab Clin North Am. 2018;47:549–55. https://doi.org/10.1016/j.ecl.2018.04.010.

Article  PubMed  Google Scholar 

Faggiano A. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story. J Endocrinol Invest. 2023. https://doi.org/10.1007/s40618-023-02170-9.10.1007/s40618-023-02170-9.

Article  PubMed  PubMed Central  Google Scholar 

Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966–73. https://doi.org/10.1093/annonc/mdh216.

Article  CAS  PubMed  Google Scholar 

Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, et al. The biological characterization of neuroendocrine tumors: The role of neuroendocrine markers. J Endocrinol Invest. 2008;31:277–86. https://doi.org/10.1007/BF03345602.

Article  CAS  PubMed  Google Scholar 

Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: The net management study. J Endocrinol Invest. 2012;35:817–23. https://doi.org/10.3275/8102.

Article  CAS  PubMed  Google Scholar 

Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol. 2022;33:6–26. https://doi.org/10.1007/s12022-022-09703-7.

Article  CAS  PubMed  Google Scholar 

Piscopo L, Zampella E, Pellegrino S, Volpe F, Nappi C, Gaudieri V, Fonti R, Vecchio SD, Cuocolo A, Klain M. Diagnosis, management and theragnostic approach of gastro-entero-pancreatic neuroendocrine neoplasms. Cancers. 2023;15:3483. https://doi.org/10.3390/cancers15133483.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18.

Article  PubMed  Google Scholar 

Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525–34.

Article  PubMed  PubMed Central  Google Scholar 

Muscogiuri G, Altieri B, Albertelli M, et al. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020;69(2):441–50. https://doi.org/10.1007/s12020-020-02331-3.

Article  CAS  PubMed  Google Scholar 

Ruggeri RM, Altieri B, Grossrubatcher E, Minotta R, Tarsitano MG, Zamponi V, Isidori AM, Faggiano A, Colao AM, NIKE Group. Sex differences in carcinoid syndrome: A gap to be closed. Rev Endocr Metab Disord. 2022;23:659–69. https://doi.org/10.1007/s11154-022-09719-8.

Article  PubMed  Google Scholar 

White BE, Russell B, Remmers S, Rous B, Chandrakumaran K, Wong KF, Van Hemelrijck M, Srirajaskanthan R, Ramage JK. Sex differences in survival from neuroendocrine neoplasia in England 2012–2018: A retrospective, population-based study. Cancers (Basel). 2023;15:1863. https://doi.org/10.3390/cancers15061863.

Article  PubMed  Google Scholar 

Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.

Article  CAS  PubMed  Google Scholar 

Eigler T, Ben-Shlomo A. Somatostatin system: Molecular mechanisms regulating anterior pituitary hormones. J Mol Endocrinol. 2014;53:R1–19.

Article  CAS  PubMed  Google Scholar 

Rorsman P, Huising MO. The somatostatin-secreting pancreatic delta-cell in health and disease. Nat Rev Endocrinol. 2018;14:404–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230–7.

Article  CAS  PubMed  Google Scholar 

Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta. 2003;1616:1–84. https://doi.org/10.1016/s0005-2736(03)00235-9.

Article  PubMed  Google Scholar 

Modlin IM, Pavel M, Kidd M, Gustafsson BI. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31:169–88. https://doi.org/10.1111/j.1365-2036.2009.04174.x.

Article  CAS  PubMed  Google Scholar 

Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs. 2015;75:847–58. https://doi.org/10.1007/s40265-015-0397-7.

Article  CAS  PubMed  Google Scholar 

Pöll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol. 2010;24:436–46. https://doi.org/10.1210/me.2009-0315.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms. Int J Mol Sci. 2019;20:3940. https://doi.org/10.3390/ijms20163940.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gatto F, Arvigo M, Ferone D. Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Invest. 2020;43:1543–53. https://doi.org/10.1007/s40618-020-01335-0.

Article  CAS  PubMed  Google Scholar 

Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152:645–54. https://doi.org/10.1530/eje.1.01876.

Article  CAS  PubMed  Google Scholar 

Gatto F, Feelders RA, Franck SE, van Koetsveld PM, Dogan F, Kros JM, Neggers SJCMM, van der Lely AJ, Lamberts SWJ, Ferone D, Hofland LJ. In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 2017;102:2009–18. https://doi.org/10.1210/jc.2017-00135.

Article  PubMed  Google Scholar 

Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89:1577–85. https://doi.org/10.1210/jc.2003-031344.P.

Article  CAS  PubMed  Google Scholar 

Vázquez-Borrego MC, Gupta V, Ibáñez-Costa A, Gahete MD, Venegas-Moreno E, Toledano-Delgado Á, et al. A somatostatin receptor subtype-3 (SST3) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumors. Clin Cancer Res. 2020;26:957–69. https://doi.org/10.1158/1078-0432.CCR-19-2154.

Article  PubMed  Google Scholar 

Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: A systematic review. Endocrine. 2017;57:366–75.

Article  CAS  PubMed  Google Scholar 

Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, et al. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr Relat Cancer. 2014;21:691–704. https://doi.org/10.1530/ERC-14-0086.

Article  CAS  PubMed  Google Scholar 

Vitale G, Dicitore A, Sciammarella C, Di Molfetta S, Rubino M, Faggiano A, Colao A. Pasireotide in the treatment of neuroendocrine tumors: A review of the literature. Endocr Relat Cancer. 2018;25:R351–64.

Article  CAS  PubMed  Google Scholar 

Mogl MT, Dobrindt EM, Buschermöhle J, Bures C, Pratschke J, Amthauer H, Wetz C, Jann H. Influence of gender on therapy and outcome of neuroendocrine tumors of gastroenteropancreatic origin: A single-center analysis. Visc Med. 2020;36:20–7. https://doi.org/10.1159/000505500.

Article  PubMed  PubMed Central  Google Scholar 

Abdel-Rahman O, Fazio N. Sex-based differences in prognosis of patients with gastroenteropancreatic-neuroendocrine neoplasms: A population-based study. Pancreas. 2021;50:727–31.

Article  CAS  PubMed  Google Scholar 

Dufourny L, Warembourg M. Colocalization of progesterone receptor and somatostatin immunoreactivities in the hypothalamus of the male and female guinea pig. Neuroendocrinology. 1996;64:215–24.

Article  CAS